Pulmonary Disease, Chronic Obstructive Clinical Trial
— 2-TELEKOLOfficial title:
Feasibility and Effect of a Follow up Tele-rehabilitation Program for Chronic Obstructive Lung Disease vs. Standard Follow up
Introduction In order to guarantee chronic patients & elderly a high quality service from
health care organizations in the coming decades, new technologies have been implemented to
treat patients from a distance. There is still a need for more studies on the efficacy and
cost-effectiveness of tele-rehabilitation (TR) and its long-term effects needs also to be
determined. To guarantee individuals with chronic obstructive pulmonary diseases (COPD) a
high quality service from health care organizations in the coming decades and economically
save the national health systems for an expensive bill for the treatment of COPD, new actions
plans has to be taken into use. Hereby, more patients can be treated with less human
resources while still sustaining or even improving today's services. The importance of such
welfare action plans has to maintain a high quality of service that individuals with COPD are
willing to accept. Here, TR seems to be a good welfare action plans. Despite proof of
improved cost-effectiveness, no studies support the benefits of TR in COPD patient with
respect to adherence, security, treatment efficacy and improved quality of life.
Aim To assess and compare the feasibility and effect of a tele-rehabilitation program with a
new and innovative TR platform (NITRP) compared to standard treatment with respect to
exercise capacity, quality of life and activities of daily living in patients with COPD.
Method and material The study is a prospective randomized controlled trial comparing the
effects of a follow-up tele-rehabilitation program and conventional follow-up rehabilitation
in patients with severe COPD. 54 patients fulfilling the inclusion criteria will be
randomized in two groups to either an 8 week follow-up tele-rehabilitation program or to
standard follow up after rehabilitation. Participants will be tested at baseline, after 8
weeks and 6 months after cessation of the training programs. In the intervention group, a
real- and a virtual physiotherapist agent will facilitate the rehabilitation.
Ethical considerations This study will not pose any risk to the patient as compared to
current practice. Participation is voluntary and the patient may at any time withdraw from
the study without consequences for future care or treatment. The questionnaires and the test
methods used are clinically recognized instruments. Signed informed consent will be obtained
from the all participants after verbal and written information and before the study starts.
The study will not be initiated before approval from the Ethics Committee and the Data
Protection Agency has been obtained. The study will follow the general research ethical rules
as expressed in the Helsinki Declaration II.
| Status | Recruiting |
| Enrollment | 54 |
| Est. completion date | January 30, 2021 |
| Est. primary completion date | December 30, 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 85 Years |
| Eligibility |
Inclusion Criteria: 1. Stable COPD 2. Signed informed consent 3. Completion of the standard rehabilitation program 4. Permanent oxygen therapy is not an obstacle for participation. Exclusion Criteria: 1. The patient has significant musculoskeletal disorders that limit his / her function levels to a degree that is not caused by dyspnea 2. The patient has pronounced dizziness, significant sensory or motor disability, dementia or terminal malignant disease 3. Serious comorbidities (unstable heart disease, irregular diabetes, known malignant disease, another disease that makes the patient unfit to participate in the study). 4. Non-compliant patient (eg. Nursing Homes Residents) 5. Participation in another project within the last 30 days 6. Mini-Mental State Examination score less than 24 points 7. Severe vision or hearing loss. 8. Non-Danish speaking. 9. Lack of will to implement the protocol. 10. Motor or sensory disease, which makes it impossible for walk training 11. Have experienced a worsening in the last 4-6 weeks 12. Musculoskeletal disorders 13. Serious heart diseases (ejection fraction <30%, daily angina, or as indicated by treating the cardiologist) 14. Can not understand informed consent 15. Other factors that inhibit the use of telerehabilitation |
| Country | Name | City | State |
|---|---|---|---|
| Denmark | Jose Cerdan | Aarhus | Danmark |
| Lead Sponsor | Collaborator |
|---|---|
| University of Aarhus | Eurostars |
Denmark,
Tsai LL, McNamara RJ, Moddel C, Alison JA, McKenzie DK, McKeough ZJ. Home-based telerehabilitation via real-time videoconferencing improves endurance exercise capacity in patients with COPD: The randomized controlled TeleR Study. Respirology. 2017 May;22(4):699-707. doi: 10.1111/resp.12966. Epub 2016 Dec 19. — View Citation
Zanaboni P, Dinesen B, Hjalmarsen A, Hoaas H, Holland AE, Oliveira CC, Wootton R. Long-term integrated telerehabilitation of COPD Patients: a multicentre randomised controlled trial (iTrain). BMC Pulm Med. 2016 Aug 22;16(1):126. doi: 10.1186/s12890-016-0288-z. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | 6 minute walk test | Change in the 6 minute walk test | measured at week 8 | |
| Secondary | 6 minute walk test | Change in the 6 minute walk test measured 6 months after cessation of the tele-rehabilitation program compared to baseline. | 6 months after cessation | |
| Secondary | Health-related quality of life | Change in total score in health-related quality of life measured by SGRQ after 8 weeks, and 6 months after cessation of the tele-rehabilitation program compared to baseline. | 8 weeks, and 6 months after cessation | |
| Secondary | Generalised Anxiety Disorder Assessment (GAD-7) | Change in total score in health-related quality of life measured by GAD-7 after 8 weeks, and 6 months after cessation of the tele-rehabilitation program compared to baseline. The GAD-7 score is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of 'not at all', 'several days', 'more than half the days', and 'nearly every day', respectively, and adding together the scores for the seven questions. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. When used as a screening tool, further evaluation is recommended when the score is 10 or greater. |
8 weeks, and 6 months after cessation | |
| Secondary | health-related quality of life measured by SGRQ | Change in component scores (symptoms, activity & impact) in health-related quality of life measured by SGRQ immediately after, and 6 months after cessation of the tele-rehabilitation program compared to baseline. | 6 months after cessation | |
| Secondary | Cost tele-rehab | Cost of the tele-rehabilitation program | 6 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
| Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
| Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
| Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
| Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
| Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
| Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
| Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
| Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
| Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
| Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
| Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
| Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
| Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
| Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
| Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
| Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
| Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|